Rolul markerilor tumorali în cancerul glandei mamare

Markerii tumorali sunt utili, în special, pentru monitorizarea tratamentului. Markerul tumoral CEA (Carcinoembrionic Antigen) îndeplinește diferite roluri în prognozarea şi evoluţia clinică a cancerului glandei mamare (CGM). Celulele canceroase produc mari cantităţi de CEA, dar acest marker se găsește şi în mod normal (în mici cantităţi) în sangele persoanelor sănătoase. Valori mari de CEA se depistează la persoane cu cancer, inclusiv cu CGM. Un alt marker tumoral al CGM, de generaţie nouă este antigenul CA 15.3, care după părerea multor autori, este un indice major în posibilităţile de pronostic şi monitorizare a evoluţiei maladiei maligne. Markerul CA 15.3 poate fi introdus ca metodă de screening în segmentul de vârstă pre- şi postmenopauză a populaţiei feminine

Biochemistry

www.elsevier.com/locate/yabio SigniWcant enhancement of Xuorescence on hybridization of a molecular beacon to a target DNA in the presence of a site-speciWc DNA nickas

Clinical evolution peculiarities of Hodgkin’s disease in pregnancy and after delivery in patients who underwent radiotherapy by radical or widening programme

Catedra Hematologie, Oncologie şi Terapie de Campanie Instituţia Medico-Sanitară Publică, Institutul de Oncologie din R.MoldovaThe influence of pregnancies (105) and deliveries (63) on Hodgkin’s disease evolution have been studied in 78 patients after radiotherapy by a radical or widening programme. There were 29 pregnancies and 5 childbirths in 27 women in the active period of Hodgkin’s disease. There was a medical abortion in 24 cases. All of them had a developing Hodgkin’s disease after pregnancy and delivery. In the remission period of Hodgkin’s disease 76 pregnancies in 51 women ended in 58 childbirths. Pregnancy was interrupted in 18 cases. Only 6 patiens in this group were detected relapses. These were more frequent (31.25%) in the cases when pregnancy occurred in the first 3 years of remission. Much more rarelly (5.6%) relapses have been reported when pregnancy occurred 4-5 years after remission set up, whereas 6 and more years after remission relapses resullting from pregnancy haven’t been revealed. Thus, it’s necessary to interrupt the pregnancy in the active Hodgkin’s disease period, because of a great risc of relapses development. It’s possible to prezerve the pregnancy in stable and long Hodgkin’s disease remission due to the minimal risc of relapses. A fost studiată influenţa în 105 cazuri de sarcină şi 63 cazuri de naşteri asupra evoluţiei limfomului Hodgkin la 78 paciente după radioterapie conform programului radical sau desfăşurat. În perioada activă a limfomului Hodgkin la 27 femei 29 de sarcini s-au terminat cu 5 naşteri. În 24 de cazuri a fost avort medical. La toate aceste paciente s-a constatat progresarea maladiei. În perioada de remisiune a limfomului Hodgkin la 51 femei 76 de sarcini s-au terminat cu 58 naşteri. În 18 cazuri sarcina a fost întreruptă. În această grupă doar la 6 bolnave s-au depistat recidive. Mai frecvent (31,25%) acestea au fost depistate în cazurile când sarcina a survenit în primii 3 ani de remisiune. Mult mai rar (5,6%) recidive s-au înregistrat când sarcina a apărut în decurs la 4-5 ani de remisiune, iar după 6 ani şi mai mult recidive în urma sarcinii nu s-au depistat. Aşadar, în perioada activă a limfomului Hodgkin sarcina necesită a fi întreruptă din cauza riscului înalt de dezvoltare a recidivelor. În cazurile remisiunilor stabile şi îndelungate sarcina poate fi păstrată, deoarece riscul dezvoltării recidivelor este minimal

Integral cross section measurement of the12C(n,p)12B reaction

The integral cross section of the12C(n, p)12B reaction was measured at the neutron time of flight facility nTOF at CERN, from the reaction threshold at 13.6 MeV up to 10 GeV, by means of the combined activation and a timeofflight technique. The integral result is expressed as the number of12B nuclei produced per single pulse of the neutron beam. A simple integral expression is given for calculating the number of produced12B nuclei from any given evaluated cross section and/or model prediction. © 2015, CERN. All rights reserved.Postprint (author's final draft

Measurement of the240Pu(n,f) cross-section at the CERN n-TOF facility: First results from EAR-2

The accurate knowledge of neutron cross-sections of a variety of plutonium isotopes and other minor actinides, such as neptunium, americium and curium, is crucial for feasibility and performance studies of advanced nuclear systems (Generation-IV reactors, Accelerator Driven Systems). In this context, the240Pu(n,f) cross-section was measured with the time-of-flight technique at the CERN n-TOF facility at incident neutron energies ranging from thermal to several MeV. The present measurement is the first to have been performed at n-TOF's newly commissioned Experimental Area II (EAR-2), which is located at the end of an 18 m neutron beam-line and features a neutron fluence that is 25-30 times higher with respect to the existing 185 m flight-path (EAR-1), as well as stronger suppression of sample-induced backgrounds, due to the shorter times-of-flight involved. Preliminary results are presented. © 2015, CERN. All rights reserved.Postprint (published version

High accuracy, high resolution 235U(n,f) cross section from n_TOF (CERN) from 18 meV to 10 keV

he version of record os available online at: http://dx.doi.org/10.1140/epja/s10050-022-00779-7U(n,f) cross section was measured in a wide energy range (18 meV–170 keV) at the n_TOF facility at CERN, relative to 6Li(n,t) and 10B(n,a) standard reactions, with high resolution and accuracy, with a setup based on a stack of six samples and six silicon detectors placed in the neutron beam. In this paper we report on the results in the region between 18 meV and 10 keV neutron energy. A resonance analysis has been performed up to 200 eV, with the code SAMMY. The resulting fission kernels are compared with the ones extracted on the basis of the resonance parameters of the most recent major evaluated data libraries. A comparison of the n_TOF data with the evaluated cross sections is also performed from thermal to 10 keV neutron energy for the energy-averaged cross section in energy groups of suitably chosen width. A good agreement, within 0.5%, is found on average between the new results and the latest evaluated data files ENDF/B-VIII.0 and JEFF-3.3, as well as with respect to the broad group average fission cross section established in the framework of the standard working group of IAEA (the so-called reference file). However, some discrepancies, of up to 4%, are still present in some specific energy regions. The new dataset here presented, characterized by a unique combination of high resolution and accuracy, low background and wide energy range, can help to improve the evaluations from the Resolved Resonance Region up to 10 keV, also reducing the uncertainties that affect this region.Peer ReviewedAquest article està escrit per 130 autors/autores: Simone Amaducci, Nicola Colonna, Luigi Cosentino, Sergio Cristallo, Paolo Finocchiaro, Milan Krtiˇcka, Cristian Massimi, Mario Mastromarco, Annamaria Mazzone, Alberto Mengoni, Stanislav Valenta, Oliver Aberle, Victor Alcayne, Józef Andrzejewski, Laurent Audouin, Victor Babiano-Suarez, Michael Bacak, Massimo Barbagallo, Samuel Bennett, Eric Berthoumieux, Jon Billowes, Damir Bosnar, Adam Brown, Maurizio Busso, Manuel Caamaño, Luis Caballero-Ontanaya, Francisco Calviño, Marco Calviani, Daniel Cano-Ott, Adria Casanovas, Francesco Cerutti, Enrico Chiaveri, Guillem Cortés, Miguel Cortés-Giraldo, Lucia-Anna Damone, Paul-John Davies, Maria Diakaki, Mirco Dietz, Cesar Domingo-Pardo, Rugard Dressler, Quentin Ducasse, Emmeric Dupont, Ignacio Durán, Zinovia Eleme, Beatriz Fernández-Domínguez, Alfredo Ferrari, Valter Furman, Kathrin Göbel, Ruchi Garg, Aleksandra Gawlik, Simone Gilardoni, Isabel Gonçalves, Enrique González-Romero, Carlos Guerrero, Frank Gunsing, Hideo Harada, Stephan Heinitz, Jan Heyse, David Jenkins, Arnd Junghans, Franz Käppeler, Yacine Kadi, Atsushi Kimura, Ingrid Knapova, Michael Kokkoris, Yuri Kopatch, Deniz Kurtulgil, Ion Ladarescu, Claudia Lederer-Woods, Helmut Leeb, Jorge Lerendegui-Marco, Sarah-Jane Lonsdale, Daniela Macina, Alice Manna, Trinitario Martínez, Alessandro Masi, Pierfrancesco Mastinu, Emilio-Andrea Maugeri, Emilio Mendoza, Veatriki Michalopoulou, Paolo Milazzo, Federica Mingrone, Javier Moreno-Soto, Agatino Musumarra, Alexandru Negret, Francisco Ogállar, Andreea Oprea, Nikolas Patronis, Andreas Pavlik, Jarosław Perkowski, Luciano Piersanti, Cristina Petrone, Elisa Pirovano, Ignacio Porras, Javier Praena, José-Manuel Quesada, Diego Ramos-Doval, Thomas Rauscher, René Reifarth, Dimitri Rochman, Carlo Rubbia, Marta Sabaté-Gilarte, Alok Saxena, Peter Schillebeeckx, DorotheaPostprint (published version

74 Ge(n, ¿) cross section below 70 keV measured at n_TOF CERN

The version of record os available online at:https://doi.org/10.1140/epja/s10050-022-00878-5Neutron capture reaction cross sections on 74Ge are of importance to determine 74Ge production during the astrophysical slow neutron capture process. We present new resonancedataon74Ge(n,¿)reactionsbelow70keVneutron energy. We calculate Maxwellian averaged cross sections, combining our data below 70 keV with evaluated cross sections at higher neutron energies. Our stellar cross sections are in agreement with a previous activation measurement performed at Forschungszentrum Karlsruhe by Marganiec et al., once their data has been re-normalised to account for an update in the reference cross section used in that experimentPeer ReviewedArticle escrit per 123 autors/autores C. Lederer-Woods, O. Aberle, J. Andrzejewski, L. Audouin, V. Bécares, M. Bacak, J. Balibrea, M. Barbagallo, S. Barros, U. Battino, F. Bečvář, C. Beinrucker, E. Berthoumieux, J. Billowes, D. Bosnar, M. Brugger, M. Caamaño, F. Calviño, M. Calviani, D. Cano-Ott, R. Cardella, A. Casanovas, D. M. Castelluccio, F. Cerutti, Y. H. Chen, E. Chiaveri, N. Colonna, G. Cortés, M. A. Cortés-Giraldo, L. Cosentino, L. A. Damone, M. Diakaki, C. Domingo-Pardo, R. Dressler, E. Dupont, I. Durán, B. Fernández-Domínguez, A. Ferrari, P. Ferreira, P. Finocchiaro, V. Furman, K. Göbel, A. R. García, A. Gawlik-Ramięga, T. Glodariu, I. F. Gonçalves, E. González-Romero, A. Goverdovski, E. Griesmayer, C. Guerrero, F. Gunsing, H. Harada, T. Heftrich, S. Heinitz, J. Heyse, D. G. Jenkins, E. Jericha, F. Käppeler, Y. Kadi, T. Katabuchi, P. Kavrigin, V. Ketlerov, V. Khryachkov, A. Kimura, N. Kivel, M. Kokkoris, M. Krtička, E. Leal-Cidoncha, H. Leeb, J. Lerendegui-Marco, S. Lo Meo, S. J. Lonsdale, R. Losito, D. Macina, J. Marganiec, T. Martínez, C. Massimi, P. Mastinu, M. Mastromarco, F. Matteucci, E. A. Maugeri, E. Mendoza, A. Mengoni, P. M. Milazzo, F. Mingrone, M. Mirea, S. Montesano, A. Musumarra, R. Nolte, A. Oprea, N. Patronis, A. Pavlik, J. Perkowski, I. Porras, J. Praena, J. M. Quesada, K. Rajeev, T. Rauscher, R. Reifarth, A. Riego-Perez, P. C. Rout, C. Rubbia, J. A. Ryan, M. Sabaté-Gilarte, A. Saxena, P. Schillebeeckx, S. Schmidt, D. Schumann, P. Sedyshev, A. G. Smith, A. Stamatopoulos, G. Tagliente, J. L. Tain, A. Tarifeño-Saldivia, L. Tassan-Got, A. Tsinganis, S. Valenta, G. Vannini, V. Variale, P. Vaz, A. Ventura, V. Vlachoudis, R. Vlastou, A. Wallner, S. Warren, M. Weigand, C. Weiss, C. Wolf, P. J. Woods, T. Wright, P. ŽugecPostprint (published version

Magnetic and structural properties of barium hexaferrite BaFe12O19 from various growth techniques

Barium hexaferrite powder samples with grains in the m-range were obtained from solid-state sintering, and crystals with sizes up to 5 mm grown from PbO, Na2CO3, and BaB2O4 fluxes, respectively. Carbonate and borate fluxes provide the largest and structurally best crystals at significantly lower growth temperatures of 1533 K compared to flux-free synthesis (1623 K). The maximum synthesis temperature can be further reduced by the application of PbO-containing fluxes (down to 1223 K upon use of 80 at % PbO), however, Pb-substituted crystals Ba1-xPbxFe12O19 with Pb contents in the range of 0.23(2) x 0.80(2) form, depending on growth temperature and flux PbO content. The degree of Pb-substitution has only a minor influence on unit cell and magnetic parameters, although the values for Curie temperature, saturation magnetization, as well as the coercivity of these samples are significantly reduced in comparison with those from samples obtained from the other fluxes. Due to the lowest level of impurities, the samples from carbonate flux show superior quality compared to materials obtained using other methods

Constraints on the dipole photon strength for the odd uranium isotopes

Nuclear level densities (NLDs) and photon strength functions (PSFs), also called ¿ -ray or radiation strength functions, represent average properties of the nucleus in the regime of excitation where individual levels and transition probabilities by ¿ decay are not readily accessible by experimental or theoretical means. They are key ingredients for statistical calculations of the reaction cross sections involving ¿ rays via the Hauser-Feshbach approach [1], like inelastic scattering or neutron capture reactions.Peer ReviewedAquest article té 124 autors/autores J. Moreno-Soto, S. Valenta, E. Berthoumieux, A. Chebboubi, M. Diakaki, W. Dridi, E. Dupont, F. Gunsing, M. Krticka, O. Litaize, O. Serot, O. Aberle, V. Alcayne, S. Amaducci, J. Andrzejewski, L. Audouin, V. Bécares, V. Babiano-Suarez, M. Bacak, M. Barbagallo, Th. Benedikt, S. Bennett, J. Billowes, D. Bosnar, A. Brown, M. Busso, M. Caamaño, L. Caballero-Ontanaya, F. Calviño, M. Calviani, D. Cano-Ott, A. Casanovas, F. Cerutti, E. Chiaveri, N. Colonna, G. Cortés, M. A. Cortés-Giraldo, L. Cosentino, Cristallo, L. A. Damone, P. J. Davies, M. Dietz, C. Domingo-Pardo, R. Dressler, Q. Ducasse, I. Durán, Z. Eleme, B. Fernández-Domínguez, A. Ferrari, P. Finocchiaro, V. Furman, K. Göbel, A. Gawlik-Rami, S. Gilardoni, I. F. Gonçalves, E. González-RomeroC. Guerrero, S. Heinitz, J. Heyse, D. G. Jenkins, A. Junghans, F. Käppeler, Y. Kadi, A. Kimura, I. Knapová, M. Kokkoris, Y. Kopatch, D. Kurtulgil, I. Ladarescu, C. Lampoudis, C. Lederer-Woods, S. J. Lonsdale, D. Macina, A. Manna, T. Martínez, A. Masi, C. Massimi, P. Mastinu, M. Mastromarco, E. A. Maugeri, A. Mazzone, E. Mendoza, A. Mengoni, V. Michalopoulou, P. M. Milazzo, F. MingroneA. Musumarra, A. Negret, R. Nolte, F. Ogállar, A. Oprea, N. Patronis, A. Pavlik, J. Perkowski, L. Piersanti, C. Petrone, E. Pirovano, I. Porras, J. Praena, J. M. Quesada, D. Ramos-Doval, T. Rauscher, R. Reifarth, D. Rochman, M. Sabaté-Gilarte, A. Saxena, P. Schillebeeckx, D. Schumann, A. Sekhar, A. G. Smith, N. V. Sosnin, P. Sprung, A. Stamatopoulos, G. Tagliente, J. L. Tain, A. Tarifeño-Saldivia, L. Tassan-Got, P. Torres-Sánchez, A. Tsinganis, J. Ulrich, S. Urlass, G. Vannini, V. Variale, P. Vaz, A. Ventura, D. Vescovi, V. Vlachoudis, R. Vlastou, A. Wallner, P. J. Woods, T. Wright, P. ŽugecPostprint (published version

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe